XP Chemistries (XPC) Q2 2025 earnings summary

Executive summary

• Achieved a major regulatory milestone with EU committee approval for high-purity capsaicin as a feed additive, with formal publication expected in September 2025 and market launch soon after.

• Focused on building sales channels, distributor partnerships, and production capacity in anticipation of commercialization.

• Successfully completed a rights issue in June, raising approximately 22.9 MSEK to support commercialization and long-term stability.

Financial highlights

• Net sales for January–June 2025 were 199 TSEK, nearly flat year-over-year (200 TSEK).

• Operating loss for the half-year was -4,642 TSEK, slightly higher than -4,569 TSEK last year.

• Net loss before tax for the half-year was -4,674 TSEK, compared to -4,546 TSEK year-over-year.

• Q2 net sales were 96 TSEK, down from 149 TSEK in Q2 2024; Q2 operating loss was -2,519 TSEK (vs. -2,243 TSEK).

• Earnings per share for H1 2025 was -0.02 SEK, improved from -0.04 SEK year-over-year.

Outlook and guidance

• Anticipates formal EU approval and product launch in early autumn 2025, transitioning from regulatory focus to commercial growth.

• Expects strengthened financial position and regulatory clearance to drive value through market entry.